Micafungin Dosing for Invasive Candidiasis
For adults with invasive candidiasis, use micafungin 100 mg daily as the standard dose, with consideration for higher doses (up to 200-400 mg daily) in critically ill patients or when treating borderline susceptible Candida species. 1, 2
Standard Adult Dosing
The established dose for invasive candidiasis in adults is 100 mg daily without a loading dose 1, 2. This recommendation comes from the 2016 IDSA guidelines and is supported by FDA labeling, which demonstrated 70.7% treatment success in the pivotal trial 2. The 2025 ECMM global guideline reinforces echinocandins as first-line therapy, though it does not specify different dosing from established standards 3.
Critical Illness Considerations
In critically ill patients, particularly those in the ICU with SOFA scores >10 or ALT >120 U/L, consider doses up to 200-400 mg daily 4, 5. Recent pharmacokinetic data reveal that:
- Standard 100 mg dosing may achieve inadequate drug exposure on day 1 of treatment 5
- A loading dose of 300 mg followed by maintenance doses of 150-200 mg may be necessary for optimal probability of target attainment 5
- The high interoccasion variability (45% for clearance) in ICU patients limits dose individualization but supports higher empirical dosing 5
This is particularly important given that 83.3% of patients treated for ≥14 days achieved successful outcomes versus lower rates with shorter durations 6.
Species-Specific Considerations
Dosing adequacy varies by Candida species and MIC:
- C. albicans and C. tropicalis: Standard 100 mg dose is effective when MIC ≤0.015 µg/mL 4
- C. glabrata: Increasing resistance patterns, including pan-echinocandin resistance, may require higher doses 4
- C. parapsilosis: Higher MICs (0.5-2 µg/mL) may necessitate dose escalation 4
- C. auris: Emerging pathogen with MICs 0.12-0.25 µg/mL; standard dosing may be insufficient 4
When MIC data are unavailable and non-albicans species are suspected, empirical high-dose therapy (up to 400 mg daily) is warranted 4.
Pediatric Dosing
Children ≥4 months and adolescents:
- 2 mg/kg daily for patients ≤40 kg (standard dose) 1, 2
- 4 mg/kg daily can be considered for treatment escalation 1
- 100 mg daily for patients >40 kg 2
Infants <4 months:
- 4 mg/kg daily is FDA-approved for candidemia and Candida peritonitis/abscesses 7, 8
- 10 mg/kg daily or higher should be considered when CNS involvement cannot be excluded, as the 4 mg/kg dose provides inadequate CNS penetration 7, 8
- This higher dose is critical given the high risk of hematogenous Candida meningoencephalitis in neonates 7
Special Populations
Neutropenic patients: Standard dosing (100 mg daily) is effective, though overall success rates may be numerically lower (63.6% vs 72.9% in non-neutropenic patients) 9, 10. Duration of neutropenia does not impact efficacy 9.
Patients with malignancy: Standard dosing is appropriate; treatment success rates are similar to those without malignancy 10.
Therapeutic Drug Monitoring
Consider TDM in critically ill patients, neonates, those with altered volume of distribution, severe hypoalbuminemia, or treatment failure 3. Target trough concentration (Cmin) >1 mg/L provides acceptable exposure based on current MIC distributions 3.
Duration of Therapy
Continue treatment for at least 2 weeks after documented clearance of Candida from bloodstream and resolution of clinical signs 1, 2. For chronic disseminated candidiasis, therapy typically extends several months until lesions resolve on imaging 1.
Critical Pitfalls to Avoid
- Do not use standard dosing blindly in ICU patients: The low PTA on day 1 and high interoccasion variability necessitate loading doses or higher maintenance doses 5
- Do not assume all Candida species respond equally: Non-albicans species are increasing, with higher MICs signaling emerging resistance 4
- Do not use 4 mg/kg in infants <4 months when CNS involvement is possible: This dose is inadequate for meningoencephalitis; use ≥10 mg/kg 7
- Do not stop therapy prematurely: Treatment for <14 days is associated with worse outcomes 6